Which Omidria patent is being asked about, and what does “Omidria patent” usually mean?
“Omidria patent” most often refers to patent coverage for the drug product (the active combination and its formulation/use) and related exclusivity protections that would control when generic or competing versions could enter. Omidria is the brand name for an intracameral/ocular irrigating solution used in cataract surgery, which has specific patent and regulatory exclusivity timelines tied to the drug’s approval.
How long does Omidria’s patent/exclusivity last, and when could generics arrive?
A generic or competitor’s entry date usually depends on two layers:
- Patent term (the last date a relevant patent remains enforceable).
- Market exclusivity and regulatory barriers (which can delay approval or marketing even if some patents expire earlier).
The exact “when” depends on which specific Omidria patents are still active and which regulatory exclusivities apply to the application pathway used by a generic (or an alternative formulation). The provided information does not include Omidria’s specific patent numbers, filing dates, or an exclusivity calendar, so the exact expiration date can’t be stated here.
Are there other exclusivities besides patents that delay an Omidria generic?
Yes. Even after patent expiration, regulatory exclusivity (for example, drug-specific exclusivity tied to the original approval) can delay approval/marketing. Patent-only timelines often do not reflect the full barrier to generic entry.
Why do companies still file patent challenges around Omidria?
Patent disputes commonly arise because:
- Different patents cover different aspects (composition, method of use, formulation, delivery device, or specific surgical use).
- Generic companies try to identify which claims are invalid or non-infringing.
- Brand companies assert remaining patents to delay approval or launch.
Without the specific Omidria patents being discussed, it isn’t possible to say which claims or litigation track applies.
What to look up if you want the exact Omidria patent expiration date
To get the correct expiration date(s), you typically need:
- The specific patent number(s) listed in FDA’s Orange Book for Omidria (drug product and any listed methods/uses).
- The “expiration” and “pediatric exclusivity” indicators (if present) from those listings.
- The earliest date any relevant patent claim is set to expire, plus any regulatory exclusivity that blocks approval/marketing.
If you share the patent number, can you summarize that specific Omidria patent?
Yes. If you provide one of the following, I can give a targeted explanation:
- The Omidria patent number you mean (e.g., US patent number).
- A link or screenshot text from the FDA Orange Book entry for Omidria.
- The country/region (US vs EU vs other), since timelines differ.
---
Sources
No sources were provided in the prompt to cite, and the exact Omidria patent identifiers and dates aren’t included. If you paste the patent number(s) or an Orange Book listing link, I can give a precise, cited answer.